Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 3/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
| ▸ | GPR39 | O43194 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933859 | 0.93 | NUDT1 (0.39) | ACVR1NUDT1GPR39 | |
| SCHEMBL3922063 | 0.90 | NUDT1 (0.45) | NUDT1GPR39HDAC8HDAC6 | |
| SCHEMBL3926831 | 0.90 | NUDT1 (0.36) | ACVR1NUDT1GPR39 | |
| SCHEMBL3922462 | 0.84 | PAK4 (0.31) | PIM1PIM2SCN9A | |
| SCHEMBL3921299 | 0.84 | ALDH1A1 (0.40) | ACVR1SCN9A | |
| SCHEMBL3926958 | 0.77 | PIM1 (0.36) | NUDT1PIM1PIM2 | |
| SCHEMBL3926142 | 0.77 | NUDT1 (0.41) | ACVR1NUDT1 | |
| SCHEMBL3931669 | 0.77 | NAPEPLD (0.39) | — | |
| SCHEMBL3935098 | 0.76 | AOC3 (0.34) | NUDT1PIM1PIM2SCN9A | |
| SCHEMBL1722967 | 0.76 | JAK2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | ACVR1 1835/4885NUDT1 4271/4885PIM1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.